AACR 2024 preview – “cancer vaccines” primed to underwhelm
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
Blenrep surprises again
After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.
AACR 2024 preview – clinical highlights and lowlights
The 2024 AACR abstract title drop features several noteworthy clinical studies.
Pfizer isn’t done with CD47
Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.
Sensei keeps its eye on VISTA
The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.
Astra takes Steap2 into human trials
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.
Warning signs for Xencor
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
